Celmatix in the news

Celmatix Inc. and Aché Laboratórios, a leading Brazilian pharmaceutical company, today announced a collaboration and license option agreement to jointly investigate a novel peripherally preferred melatonin receptor agonist, discovered by Aché, for Women's Health indications. Today’s news follows Celmatix’s April announcement of the second of its three internal drug programs, targeting melatonin receptors outside of the central nervous system (CNS) to address a critical gap in the market for effective first-line treatments for a range of women’s health indications, starting with polycystic ovary syndrome (PCOS).

Celmatix Inc. today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug. The innovative investigational product has the potential to revolutionize fertility treatments. The announcement coincides with the annual meeting of the European Society of Human Reproduction and Embryology (ESHRE), currently underway in Copenhagen, Denmark.

Celmatix Inc. today announced that Dr. Susan Herbert has joined the company’s board of advisors. Dr. Herbert joins as the company announces the launch of a novel drug development program supporting ovarian health throughout a women’s lifespan adding to their next generation of interventions and advancements in women’s health.

Celmatix Inc. today announced its latest drug program, which is targeting melatonin receptors outside of the central nervous system (CNS). The therapeutic drug will address a critical gap in the market for effective first-line treatments for a range of women’s health indications, starting with Polycystic Ovary Syndrome (PCOS) and with the potential to expand into the treatment of endometriosis and menopausal symptoms.

Celmatix Inc. today announced findings from its long-term collaboration with researchers from the University of Oxford and 24 other institutions to decode the genetic basis of endometriosis, a condition that globally impacts 1 in 10 women*. The study, published today in Nature Genetics, is the largest study on endometriosis genetics conducted to date and includes DNA from 60,600 women with endometriosis and 701,900 controls.

Celmatix Inc. today announced that a fourth milestone has been achieved in its five-year, multi-target alliance with Evotec. The milestone was triggered by Evotec and Bayer AG advancing a second drug program, centered around a novel Celmatix-identified drug target, into hit-identification.

Celmatix Inc. today announced that Craig Bolton has been appointed as General Counsel. Bolton joins the Celmatix executive team after representing the biotech as outside counsel since 2019 and will play a critical role in supporting the company in ongoing therapeutic pipeline expansion and progress of their lead AMHR2 agonist program.

Celmatix Inc. today announced that Reproductive Endocrinology pioneer Dr. Bart CJM Fauser, MD, PhD, FRCOG, will join and Chair its Scientific Advisory Board and newly-formed Clinical Trial Steering Committee.

Celmatix Inc. today announced the identification of a novel AMHR2 agonist compound that has demonstrated robust biological activity in multiple therapeutically relevant preclinical assays and a pharmacokinetic profile consistent with the desired product profile for an injectable drug. The program, which was a product of Celmatix’s decade-long focus on identifying novel biomarkers and drug targets for women’s health, has a planned first clinical indication in the prevention of premature menopause in women undergoing chemotherapy. Loss of ovarian function and menopause are accelerated by approximately 1.5 years for each month a woman receives chemotherapy treatment.

Celmatix Inc. today announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec. The milestone was triggered by Evotec and Bayer AG advancing a drug program, centered around a novel Celmatix-identified drug target, into hit-identification.